Algenpantucel-L immunotherapy in pancreatic adenocarcinoma

Pancreatic adenocarcinoma is the 4th leading cause of cancer death in the USA and the EU. A minority of patients presents with surgically resectable and potentially curable disease, but among these, 80% are destined to relapse and overall survival rates with adjuvant chemotherapy average 24 months....

Full description

Saved in:
Bibliographic Details
Published in:Immunotherapy 2016-02, Vol.8 (2), p.117-125
Main Authors: Coveler, Andrew L, Rossi, Gabriela R, Vahanian, Nicholas N, Link, Charles, Chiorean, E Gabriela
Format: Article
Language:English
Subjects:
Adenocarcinoma
algenpantucel-L
Antigens
Cancer therapies
Chemotherapy
Clinical trials
Cytotoxicity
Dendritic cells
Gene expression
Genetic engineering
Immunotherapy
Medical prognosis
Melanoma
Metastases
Metastasis
Mutation
Pancreatic cancer
Patients
Peptides
Prostate
Proteins
Surgery
Telomerase
Tumor cells
Tumors
Vaccines
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Pancreatic adenocarcinoma is the 4th leading cause of cancer death in the USA and the EU. A minority of patients presents with surgically resectable and potentially curable disease, but among these, 80% are destined to relapse and overall survival rates with adjuvant chemotherapy average 24 months. Immunotherapy is a promising therapeutic option and a potential paradigm shift in the treatment of patients with pancreatic cancer, and may be particularly effective when used early in the disease course to prevent metastatic spread. Algenpantucel-L (HyperAcute™ Pancreas, NewLink Genetics, Ames, IA, USA) is a whole-cell immunotherapy consisting of irradiated allogeneic pancreatic cancer cells genetically engineered to express the murine enzyme α-GT, which results in hyperacute rejection of the tumor cells with complement- and antibody-dependent cytotoxicity. Phase II clinical trial data has been encouraging, particularly for patients who demonstrated humoral immunologic responses. Here, we report preliminary results and biomarkers correlations with clinical activity of algenpantucel-L in pancreatic cancer.
ISSN:1750-743X
1750-7448
DOI:10.2217/imt.15.113